Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug765 | Clinical Trial Matching Wiki | 0.71 |
drug610 | COVID-19 convalescent plasma Wiki | 0.32 |
Name (Synonyms) | Correlation | |
---|---|---|
D016889 | Endometrial Neoplasms NIH | 0.71 |
D004938 | Esophageal Neoplasms NIH | 0.71 |
D013274 | Stomach Neoplasms NIH | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D012878 | Skin Neoplasms NIH | 0.71 |
D009423 | Nervous System Neoplasms NIH | 0.71 |
D007680 | Kidney Neoplasms NIH | 0.71 |
D016543 | Central Nervous System Neoplasms NIH | 0.71 |
D005909 | Glioblastoma NIH | 0.71 |
D008113 | Liver Neoplasms NIH | 0.71 |
D007822 | Laryngeal Neoplasms NIH | 0.71 |
D013736 | Testicular Neoplasms NIH | 0.71 |
D002292 | Carcinoma, Renal Cell NIH | 0.50 |
D002583 | Uterine Cervical Neoplasms NIH | 0.50 |
D012004 | Rectal Neoplasms NIH | 0.50 |
D018281 | Cholangiocarcinoma NIH | 0.50 |
D010190 | Pancreatic Neoplasms NIH | 0.41 |
D006258 | Head and Neck Neoplasms NIH | 0.41 |
D002277 | Carcinoma NIH | 0.35 |
D003110 | Colonic Neoplasms NIH | 0.35 |
D001943 | Breast Neoplasms NIH | 0.32 |
D008175 | Lung Neoplasms NIH | 0.29 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0100634 | Neuroendocrine neoplasm HPO | 1.00 |
HP:0002896 | Neoplasm of the liver HPO | 0.71 |
HP:0008069 | Neoplasm of the skin HPO | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0012114 | Endometrial carcinoma HPO | 0.71 |
HP:0100006 | Neoplasm of the central nervous system HPO | 0.71 |
HP:0010788 | Testicular neoplasm HPO | 0.71 |
HP:0009726 | Renal neoplasm HPO | 0.71 |
HP:0012174 | Glioblastoma multiforme HPO | 0.71 |
HP:0100751 | Esophageal neoplasm HPO | 0.71 |
HP:0004375 | Neoplasm of the nervous system HPO | 0.71 |
HP:0006753 | Neoplasm of the stomach HPO | 0.71 |
HP:0100605 | Neoplasm of the larynx HPO | 0.71 |
HP:0005584 | Renal cell carcinoma HPO | 0.50 |
HP:0100743 | Neoplasm of the rectum HPO | 0.50 |
HP:0030153 | Cholangiocarcinoma HPO | 0.50 |
HP:0030079 | Cervix cancer HPO | 0.50 |
HP:0002894 | Neoplasm of the pancreas HPO | 0.41 |
HP:0012288 | Neoplasm of head and neck HPO | 0.41 |
HP:0030731 | Carcinoma HPO | 0.35 |
HP:0003003 | Colon cancer HPO | 0.35 |
HP:0003002 | Breast carcinoma HPO | 0.32 |
HP:0100526 | Neoplasm of the lung HPO | 0.29 |
Navigate: Correlations HPO
There are 2 clinical trials
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Description: CTE Accrual
Measure: Proportion of patients Eligible for CTE versus Actual CTE Time: Through study completion, an average of 1 yearDescription: OS
Measure: Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: PFS
Measure: Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis Time: 4 yearsDescription: To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire
Measure: Identification of Barriers to CTE Time: Through study completion, an average of 1 yearDescription: To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).
Measure: Real World Data Analytics Time: Through study completion, an average of 1 yearDescription: VTB Use Rate
Measure: Virtual Tumor Board Utilization Time: Through study completion, an average of 1 yearDescription: Time to CTE
Measure: Time from Intervention to Actual CTE (months) Time: Through study completion, an average of 1 yearA huge number of initiatives about COVID-19 are ongoing and a growing number of publications regard the correlation between cancer patients in general and SARS-CoV-2 infection. Although it has been reported that cancer patients are at a higher risk of SARS-CoV-2 infection and COVID-19 complications, data collection about cases of NEN patients SARS-CoV-2 positive are scattered and related to single countries or institutions. Because of that and due to the rarity and heterogeneity of NEN it will be hard to have homogeneous, reliable, representative and reproducible data for drawing adequate clinical recommendations about NEN patients and COVID-19. Therefore we propose a global collection of data through an international database to describe and monitor NEN patients with SARS-CoV-2 infection. This retrospective/prospective collection of data can create a solid basis to check frequence of events, clinical management, clinical outcome, demographic, geographical, clinical and biological correlations. This will be helpful for the clinical and scientific community to get reliable information for a homogeneous clinical management of NEN patients during COVID-19 pandemic. The main goal is to get the as wide as possible representativity of the world situation.
Description: To evaluate the correlation between SARS-CoV-2 infection and the following parameters: major comorbidities, severe overall events (including death), chemotherapy for neuroendocrine tumor (NET), chemotherapy for neuroendocrine carcinoma (NEC), everolimus therapy, immunotherapy, peptide receptor radionuclide therapy (PRRT) and surgery or radiotherapy within the last 2 months.
Measure: Correlation between clinical parameters and SARS-CoV-2 infection Time: 01/2020 - 12/2020Description: To evaluate the impact of SARS-CoV-2 Infection in NEN patients
Measure: Clinical outcome of SARS-CoV-2 Infection Time: 01/2020 - 12/2020Description: demographic features of SARS-CoV-2 infected NEN patients
Measure: major demographic features Time: 01/2020 - 12/2020Description: Rate of grade, stage, status and primary site of NENs
Measure: type of NEN Time: 01/2020 - 12/2020Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports